PhaseBio Pharmaceuticals Inc
OTC:PHASQ
PhaseBio Pharmaceuticals Inc
OTC:PHASQ
Price:
0.0001
USD
Market Closed
Market Cap:
$49.9
Relative Value
There is not enough data to reliably calculate the relative value of PHASQ.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PHASQ
Relative Value
Base Case
Not Available
Multiples Across Competitors
PHASQ Competitors Multiples
PhaseBio Pharmaceuticals Inc Competitors
PhaseBio Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
PhaseBio Pharmaceuticals Inc
OTC:PHASQ
|
49.9 USD | 0 | -0 | 0.1 | 0.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
411.5B USD | 6.9 | 175.3 | 16.9 | 24 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
201.1B USD | 5.5 | 26.1 | 14.9 | 14.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
192.5B USD | 6.5 | 22.6 | 15.4 | 15.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.8B USD | 10.1 | 30.6 | 23.4 | 24.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.8B USD | 5.8 | 18.6 | 14.2 | 16.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.6B EUR | 14.3 | 33.7 | 57.9 | 59.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
73.9B AUD | 3.3 | 17.1 | 11.7 | 14.6 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
